Research programme: interleukin 1 beta inhibitors - Opsona
Alternative Names: IL1-ß inhibitor - OpsonaLatest Information Update: 28 Feb 2019
At a glance
- Originator Opsona Therapeutics
- Class Small molecules
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Inflammation in Ireland
- 03 Feb 2017 The interleukin 1 beta inhibitor research programme is still under early research for Inflammation in Ireland (Opsona Therapeutics pipeline, February 2017)
- 03 Feb 2017 Research programme: interleukin 1 beta inhibitors - Opsona is available for licensing/partnering as of 03 Feb 2017. http://www.opsona.com/Inflammasome